Toggle light / dark theme

The longevity healthtech market is an investor’s dream

Is the longevity industry the healthtech investment trend?

Forbes contributor and finance expert Richard Eisenberg discusses with Taimur Hyat, Chief Strategy Officer at Prudential Financial’s investment arm ($963 billion of funds under management).

Hyat shared his views on investinginto the ageing industry. He noted ‘the first wave of tech and apps was designed with millennials in mind — pizza delivery and Uber. The next wave of platforms and technology will be designed with the needs of the elderly in mind.

Walmart Opens Tech Incubator In Austin

Walmart has opened a new tech incubator in Austin to focus on emerging technologies.

Engineers, developers and scientists at the incubator are working on the future of shopping and exploring machine learning, artificial intelligence and natural language processing, according to a blog post by Walmart.

“The work we’re doing is ultimately about enabling our coworkers to be even more impactful in their jobs,” stated Rachel Brynsvold, data scientist at the lab. “I also see lots of opportunities to make financial impact for the company, which contributes to Walmart’s mission to help people save money and live better.”

All-star team of synthetic biologists raise $53 million for cancer therapy startup Senti

A who’s-who from the world of synthetic biological research have come together to launch Senti Biosciences with $53 million in funding from a slew of venture capital investors.

Led by Tim Lu, a longtime researcher at the Massachusetts Institute of Technology and one of the founding fathers of synthetic biology, Senti’s aim is nothing less than developing therapies that are tailored to an individual’s unique biology — and their first target is cancer.

Here’s how Lu described a potential cancer treatment using Senti’s technology to me. “We take a cell derived from humans that we can insert our genetic circuits into… we insert the DNA and encoding and deliver those cells via an IV infusion. We have engineered the cells to locate where the tumors are… What we’ve been doing is engineering those cells to selectively trigger an immune response against the tumor.”

Will 100 be the new 60? Stem cell start-up that raised $250 million could extend lifespan

Longevity become hottest object for investments;

Startup founded 5 moths ago just raised $250 million.


The start-up, which launched in September and is headquartered in Warren, N.J., announced Thursday it has raised $250 million in venture capital from global biopharmaceutical company Celgene, biotechnology company United Therapeutics Corporation, biopharmaceutical company Sorrento Therapeutics, DNA sequencing and machine learning company Human Longevity, Inc.

Its biological “Band-Aids” are used to accelerate the treatment of wounds and burns resulting from injury or any manner of reconstructive surgery, and its injectable stem cell products can accelerate the repair of a tissue or organ. These restorative products cost from a few hundred to a few thousand dollars per unit, according to Hariri. Celularity bought its stem cell bandage business earlier in January when it acquired Alliqua BioMedical for $29 million.

Behind the simulations imagining the nuclear apocalypse

Security experts say more of these hands-on demonstrations are needed to get an industry traditionally focused on physical protection to think more creatively about growing cyber threats. The extent to which their advice is heeded will determine how prepared nuclear facilities are for the next attack.

“Unless we start to think more creatively, more inclusively, and have cross-functional thinking going into this, we’re going to stay with a very old-fashioned [security] model which I think is potentially vulnerable,” said Roger Howsley, executive director of the World Institute for Nuclear Security (WINS).

The stakes are high for this multibillion-dollar sector: a cyberattack combined with a physical one could, in theory, lead to the release of radiation or the theft of fissile material. However remote the possibility, the nuclear industry doesn’t have the luxury of banking on probabilities. And even a minor attack on a plant’s IT systems could further erode public confidence in nuclear power. It is this cruelly small room for error that motivates some in the industry to imagine what, until fairly recently, was unimaginable.

China publishes more scientific articles than the U.S.

A new analysis of global science and engineering competence shows that the United States is struggling to fight off an increasingly competitive China.

The numbers: According to the National Science Foundation, China published over 426,000 research papers in 2016. America pumped out almost 409,000. If you consider the number of citations for those papers, a measure of the influence they have in the scientific community, America does better—it placed third internationally, while China comes in fifth (Sweden and Switzerland took the top spots).

Strengths elsewhere: The report does, however, note that America invests the most in R&D, attracts the most venture capital, and awards the most advanced degrees compared with every other nation in the world.